PURPOSE:To develop, implement and demonstrate a data driven strategy to identify 'suspects' and 'outliers' in datasets of biometric measurements taken before cataract surgery. METHODS:A shallow autoencoder with one hidden layer and 3 neurons was trained on a large multicentre dataset (N = 152,397, 9 clinical centres) from the IOLMaster 700 including axial length (AL), central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and corneal front surface radius (R). Measurements were identified as 'suspects' or 'outliers' depending on the mean squared prediction error. Training was performed on 7 of the 9 datasets, and the remaining 2 datasets were used to evaluate the performance of the autoencoder. RESULTS:Crossvalidation proved that the autoencoder with 3 neurons showed no noticeable overfitting. Measurements were marked as 'suspects' or 'outliers' based on the 95% and 99% quantiles as derived from the mean squared error with the training data. After piecewise linear correction of the autoencoder prediction error to correct for trend errors probably due to internal calibrations of the biometer, the autoencoder successfully identified potentially faulty measurements for the 2 test datasets. CONCLUSIONS:Autoencoders are quite popular for different application fields in engineering, and could also help in ophthalmology to identify potentially faulty biometric measurements which could lead to refractive surprises if used for intraocular lens power calculation. Further studies are required to validate this concept with other parameters or datasets from other biometers.
Axillary surgery in breast cancer has undergone a profound transformation in recent decades. While axillary lymph node dissection (ALND) was the unquestioned standard until the 1990s [1], associated morbidity including lymphedema rates as high as 25
Background/Objectives: The transradial approach is widely used for vascular access in many disciplines. Radial artery occlusion (RAO) is a frequent sequel, and hand/arm pain affects 7.8% of patients. We aimed to elucidate whether RAO or ulnar artery occlusion (UAO) causes impaired neural blood flow and, thus, if symptoms may be attributable to claudication or nerve damage. Methods: Forty healthy volunteers (73% female), with a mean age of 38 years and without clinical or sonographic signs of carpal tunnel syndrome, were included. All underwent a standardized ultrasound examination (Aplio i800 and i22LH8 linear transducer, Canon Medical Systems) of the forearm, investigating the median nerve and its intraneural blood flow as well as the vascular status of the limb. The radial and ulnar arteries were then sequentially compressed, while changes to intraneural blood flow were noted. Thereafter, the (reverse) Barbeau test and the (inverse) modified Allen Test (MAT) were performed. Results: Simulated RAO and UAO halted intraneural blood flow in 65% and 62.5% of individuals, respectively. A total of 32.5% of participants reported discomfort in the hand/arm. Absent flow during occlusion was found at a significantly higher rate in symptomatic individuals. MAT and inverse MAT were abnormal (>10 s) in 17.5% and 7.5% of patients. Barbeau and reverse Barbeau produced type D results in 15% and 20%, respectively. Conclusions: Both simulated RAO and UAO caused the cessation of intraneural blood flow of the median nerve in two-thirds of participants, and a large proportion reported symptoms. MAT and Barbeau tests did not seem to be useful in predicting impaired neural blood flow.
BACKGROUND/AIMS:Posterior capsule opacification (PCO) is the most frequent long-term complication after cataract surgery, caused by proliferation of residual lens epithelial cells (LECs). Metformin, a common antidiabetic drug with antifibrotic properties, may act as a pharmacological modulator of this process. The purpose was to assess whether systemically administered metformin reaches the human lens capsule and inhibits LEC proliferation at physiologically relevant concentrations. METHODS:Metformin concentrations were quantified in serum and lens capsule tissue of patients with type 2 diabetes mellitus undergoing cataract surgery using high performance liquid chromatography-tandem mass spectrometry. Patients were stratified into low-dose (≤1000 mg/day) and high-dose (>1000 mg/day) groups. Additionally, anterior lens capsules from non-diabetic donors were cultured with or without metformin (0.75 pg/µL), and LEC proliferation was monitored for 14 days by live-cell imaging. RESULTS:Metformin was detectable in both serum and capsule specimens, with a significant correlation between compartments (r=0.553, p=0.011). Capsule concentrations were similar across dose groups, while serum levels were higher in the low-dose group. In vitro, metformin significantly reduced LEC proliferation compared with controls (p<0.001). CONCLUSION:Systemically administered metformin reaches the human lens capsule in vivo and suppresses LEC proliferation in vitro at clinically relevant concentrations. These findings provide first clinical and experimental evidence supporting metformin as a potential pharmacological adjunct to current strategies for PCO prevention.
Die Leitlinie nimmt Bezug auf die Diagnostik einschließlich begleitender Autoimmunerkrankungen bei Typ-1-Diabetes mellitus, die Insulintherapie und die glykämischen Zielwerte.